Crysvita Európai Unió - magyar - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - kábítószerek csontbetegségek kezelésére - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Aqumeldi Európai Unió - magyar - EMA (European Medicines Agency)

aqumeldi

proveca pharma limited - enalapril (maleate) - szív elégtelenség - a renin-angiotenzin rendszerre ható szerek - treatment of heart failure.